Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy

Until recently, measles exposures were relatively rare and so, consequently, were an afterthought for cancer patients and/or blood and marrow transplantation recipients and their providers. Declines in measles herd immunity have reached critical levels in many communities throughout the United States due to increasing vaccine hesitancy, so that community-based outbreaks have occurred. The reemergence of measles as a clinical disease has raised serious concerns among immunocompromised patients and those who work within the cancer and hematopoietic cell transplantation (HCT) community.

Source: Biology of Blood and Marrow Transplantation - August 4, 2019 Category: Hematology Authors: Steven A. Pergam, Janet A. Englund, Mini Kamboj, Hayley A. Gans, Jo-Anne H. Young, Joshua A. Hill, Bipin Savani, Roy F. Chemaly, Sanjeet S. Dadwal, Jan Storek, Jeffery Duchin, Paul A. Carpenter Source Type: research